Results of phase I studies illustrated a potential for MK-8931 in the treatment of AD, as MK-8931 was found to be generally well tolerated and was able to reduce mean CSF concentrations of the Aβ proteins: Aβ40, Aβ42, and soluble β fragment of APP [87,88]. The gene discussed is APP; the disease is Alzheimer disease.